Cover Image
Market Research Report
Product code 
1050661

Treatment-Resistant Depression (TRD) - Market Insight, Epidemiology and Market Forecast -2032

Published: Pre-Order | DelveInsight Business Research LLP | 200 Pages | Delivery time: 2-10 business days

Price

Back to Top
Treatment-Resistant Depression (TRD) - Market Insight, Epidemiology and Market Forecast -2032
Published: Pre-Order
DelveInsight Business Research LLP
Content info: 200 Pages
Delivery time: 2-10 business days
  • Description
  • Table of Contents
  • List of Tables

DelveInsight's "Treatment-Resistant Depression (TRD)- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Treatment-Resistant Depression (TRD), historical and forecasted epidemiology as well as the Treatment-Resistant Depression (TRD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Treatment-Resistant Depression (TRD) market report provides current treatment practices, emerging drugs, Treatment-Resistant Depression (TRD) market share of the individual therapies, current and forecasted Treatment-Resistant Depression (TRD) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Treatment-Resistant Depression (TRD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Treatment-Resistant Depression (TRD) Disease Understanding and Treatment Algorithm

The DelveInsight Treatment-Resistant Depression (TRD) market report gives a thorough understanding of the Treatment-Resistant Depression (TRD) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Treatment-Resistant Depression (TRD).

Treatment

It covers the details of conventional and current medical therapies available in the Treatment-Resistant Depression (TRD) market for the treatment of the condition. It also provides Treatment-Resistant Depression (TRD) treatment algorithms and guidelines in the United States, Europe, and Japan.

Treatment-Resistant Depression (TRD) Epidemiology

The Treatment-Resistant Depression (TRD) epidemiology division provide insights about historical and current Treatment-Resistant Depression (TRD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Treatment-Resistant Depression (TRD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Treatment-Resistant Depression (TRD) Epidemiology

The epidemiology segment also provides the Treatment-Resistant Depression (TRD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Treatment-Resistant Depression (TRD) Drug Chapters

Drug chapter segment of the Treatment-Resistant Depression (TRD) report encloses the detailed analysis of Treatment-Resistant Depression (TRD) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Treatment-Resistant Depression (TRD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Treatment-Resistant Depression (TRD) treatment.

Treatment-Resistant Depression (TRD) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Treatment-Resistant Depression (TRD) treatment.

Treatment-Resistant Depression (TRD) Market Outlook

The Treatment-Resistant Depression (TRD) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Treatment-Resistant Depression (TRD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Treatment-Resistant Depression (TRD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Treatment-Resistant Depression (TRD) market in 7MM is expected to change in the study period 2019-2032.

Key Findings

This section includes a glimpse of the Treatment-Resistant Depression (TRD) market in 7MM.

The United States Market Outlook

This section provides the total Treatment-Resistant Depression (TRD) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Treatment-Resistant Depression (TRD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Treatment-Resistant Depression (TRD) market size and market size by therapies in Japan is also mentioned.

Treatment-Resistant Depression (TRD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Treatment-Resistant Depression (TRD) market or expected to get launched in the market during the study period 2019-2032. The analysis covers Treatment-Resistant Depression (TRD) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Treatment-Resistant Depression (TRD) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Treatment-Resistant Depression (TRD) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Treatment-Resistant Depression (TRD) emerging therapies.

Reimbursement Scenario in Treatment-Resistant Depression (TRD)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Treatment-Resistant Depression (TRD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Treatment-Resistant Depression (TRD) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Treatment-Resistant Depression (TRD) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Treatment-Resistant Depression (TRD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Treatment-Resistant Depression (TRD) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Treatment-Resistant Depression (TRD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Treatment-Resistant Depression (TRD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Treatment-Resistant Depression (TRD) market

Report Highlights:

  • In the coming years, Treatment-Resistant Depression (TRD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Treatment-Resistant Depression (TRD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Treatment-Resistant Depression (TRD). Launch of emerging therapies will significantly impact the Treatment-Resistant Depression (TRD) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Treatment-Resistant Depression (TRD)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Treatment-Resistant Depression (TRD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Treatment-Resistant Depression (TRD) Pipeline Analysis
  • Treatment-Resistant Depression (TRD) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Treatment-Resistant Depression (TRD) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Treatment-Resistant Depression (TRD) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Treatment-Resistant Depression (TRD) Report Assessment

Current Treatment Practices

  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Treatment-Resistant Depression (TRD) market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Treatment-Resistant Depression (TRD) total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Treatment-Resistant Depression (TRD) market size during the forecast period (2019-2032)?
  • At what CAGR, the Treatment-Resistant Depression (TRD) market is expected to grow in 7MM during the forecast period (2019-2032)?
  • What would be the Treatment-Resistant Depression (TRD) market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the Treatment-Resistant Depression (TRD) market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Treatment-Resistant Depression (TRD)?
  • What is the historical Treatment-Resistant Depression (TRD) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Treatment-Resistant Depression (TRD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Treatment-Resistant Depression (TRD)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Treatment-Resistant Depression (TRD) during the forecast period (2019-2032)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Treatment-Resistant Depression (TRD) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Treatment-Resistant Depression (TRD) in the USA, Europe, and Japan?
  • What are the Treatment-Resistant Depression (TRD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Treatment-Resistant Depression (TRD)?
  • How many therapies are developed by each company for Treatment-Resistant Depression (TRD) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Treatment-Resistant Depression (TRD) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Treatment-Resistant Depression (TRD) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Treatment-Resistant Depression (TRD) and their status?
  • What are the key designations that have been granted for the emerging therapies for Treatment-Resistant Depression (TRD)?
  • What are the global historical and forecasted market of Treatment-Resistant Depression (TRD)?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Treatment-Resistant Depression (TRD) market
  • To understand the future market competition in the Treatment-Resistant Depression (TRD) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Treatment-Resistant Depression (TRD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Treatment-Resistant Depression (TRD) market
  • To understand the future market competition in the Treatment-Resistant Depression (TRD) market

Table of Contents

1. Key Insights

2. Executive Summary of Treatment-Resistant Depression (TRD)

3. Competitive Intelligence Analysis for Treatment-Resistant Depression (TRD)

4. Treatment-Resistant Depression (TRD): Market Overview at a Glance

  • 4.1. Treatment-Resistant Depression (TRD) Total Market Share (%) Distribution in 2019
  • 4.2. Treatment-Resistant Depression (TRD) Total Market Share (%) Distribution in 2032

5. Treatment-Resistant Depression (TRD): Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Treatment-Resistant Depression (TRD) Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Treatment-Resistant Depression (TRD) Epidemiology Scenario in the 7MM (2019-2032)
  • 7.4. United States Epidemiology
    • 7.4.1. Treatment-Resistant Depression (TRD) Epidemiology Scenario in the United States (2019-2032)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Treatment-Resistant Depression (TRD) Epidemiology Scenario in Germany (2019-2032)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Treatment-Resistant Depression (TRD) Epidemiology Scenario in France (2019-2032)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Treatment-Resistant Depression (TRD) Epidemiology Scenario in Italy (2019-2032)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Treatment-Resistant Depression (TRD) Epidemiology Scenario in Spain (2019-2032)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Treatment-Resistant Depression (TRD) Epidemiology Scenario in the United Kingdom (2019-2032)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Treatment-Resistant Depression (TRD) Epidemiology Scenario in Japan (2019-2032)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Treatment-Resistant Depression (TRD) Treatment and Management
  • 8.2. Treatment-Resistant Depression (TRD) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Treatment-Resistant Depression (TRD) Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial
  • List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile
  • List to be continued in report

13. Treatment-Resistant Depression (TRD): Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Treatment-Resistant Depression (TRD) Market Size in 7MM
  • 13.3. Treatment-Resistant Depression (TRD) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Treatment-Resistant Depression (TRD) Total Market Size in the United States
    • 15.1.2. Treatment-Resistant Depression (TRD) Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Treatment-Resistant Depression (TRD) Total Market Size in Germany
    • 15.3.2. Treatment-Resistant Depression (TRD) Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Treatment-Resistant Depression (TRD) Total Market Size in France
    • 15.4.2. Treatment-Resistant Depression (TRD) Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Treatment-Resistant Depression (TRD) Total Market Size in Italy
    • 15.5.2. Treatment-Resistant Depression (TRD) Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Treatment-Resistant Depression (TRD) Total Market Size in Spain
    • 15.6.2. Treatment-Resistant Depression (TRD) Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Treatment-Resistant Depression (TRD) Total Market Size in the United Kingdom
    • 15.7.2. Treatment-Resistant Depression (TRD) Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Treatment-Resistant Depression (TRD) Total Market Size in Japan
    • 15.8.3. Treatment-Resistant Depression (TRD) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Treatment-Resistant Depression (TRD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

  • The table of contents is not exhaustive; the final content may vary.

List of Tables

  • Table 1: 7MM Treatment-Resistant Depression (TRD) Epidemiology (2019-2032)
  • Table 2: 7MM Treatment-Resistant Depression (TRD) Diagnosed and Treatable Cases (2019-2032)
  • Table 3: Treatment-Resistant Depression (TRD) Epidemiology in the United States (2019-2032)
  • Table 4: Treatment-Resistant Depression (TRD) Diagnosed and Treatable Cases in the United States (2019-2032)
  • Table 5: Treatment-Resistant Depression (TRD) Epidemiology in Germany (2019-2032)
  • Table 6: Treatment-Resistant Depression (TRD) Diagnosed and Treatable Cases in Germany (2019-2032)
  • Table 7: Treatment-Resistant Depression (TRD) Epidemiology in France (2019-2032)
  • Table 8: Treatment-Resistant Depression (TRD) Diagnosed and Treatable Cases in France (2019-2032)
  • Table 9: Treatment-Resistant Depression (TRD) Epidemiology in Italy (2019-2032)
  • Table 10: Treatment-Resistant Depression (TRD) Diagnosed and Treatable Cases in Italy (2019-2032)
  • Table 11: Treatment-Resistant Depression (TRD) Epidemiology in Spain (2019-2032)
  • Table 12: Treatment-Resistant Depression (TRD) Diagnosed and Treatable Cases in Spain (2019-2032)
  • Table 13: Treatment-Resistant Depression (TRD) Epidemiology in the UK (2019-2032)
  • Table 14: Treatment-Resistant Depression (TRD) Diagnosed and Treatable Cases in the UK (2019-2032)
  • Table 15: Treatment-Resistant Depression (TRD) Epidemiology in Japan (2019-2032)
  • Table 16: Treatment-Resistant Depression (TRD) Diagnosed and Treatable Cases in Japan (2019-2032)
  • Table 17: Drug Name, Clinical Trials by Recruitment status
  • Table 18: Drug Name, Clinical Trials by Zone
  • Table 19: Total Seven Major Market Size in USD, Million (2019-2032)
  • Table 20: Region-wise Market Size in USD, Million (2019-2032)
  • Table 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)
  • Table 22: United States Market Size in USD, Million (2019-2032)
  • Table 23: United States Market Size by Therapy in USD, Million (2019-2032)
  • Table 24: Germany Market Size in USD, Million (2019-2032)
  • Table 25: Germany Market Size by Therapy in USD, Million (2019-2032)
  • Table 26: France Market Size in USD, Million (2019-2032)
  • Table 27: France Market Size by Therapy in USD, Million (2019-2032)
  • Table 28: Italy Market Size in USD, Million (2019-2032)
  • Table 29: Italy Market Size by Therapy in USD, Million (2019-2032)
  • Table 30: Spain Market Size in USD, Million (2019-2032)
  • Table 31: Spain Market Size by Therapy in USD, Million (2019-2032)
  • Table 32: United Kingdom Market Size in USD, Million (2019-2032)
  • Table 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)
  • Table 34: Japan Market Size in USD, Million (2019-2032)
  • Table 35: Japan Market Size by Therapy in USD, Million (2019-2032)

The list of tables is not exhaustive; the final content may vary

List of Figures

  • Figure 1: 7MM Treatment-Resistant Depression (TRD) Epidemiology (2019-2032)
  • Figure 2: 7MM Treatment-Resistant Depression (TRD) Diagnosed and Treatable Cases (2019-2032)
  • Figure 3: Treatment-Resistant Depression (TRD) Epidemiology in the United States (2019-2032)
  • Figure 4: Treatment-Resistant Depression (TRD) Diagnosed and Treatable Cases in the United States (2019-2032)
  • Figure 5: Treatment-Resistant Depression (TRD) Epidemiology in Germany (2019-2032)
  • Figure 6: Treatment-Resistant Depression (TRD) Diagnosed and Treatable Cases in Germany (2019-2032)
  • Figure 7: Treatment-Resistant Depression (TRD) Epidemiology in France (2019-2032)
  • Figure 8: Treatment-Resistant Depression (TRD) Diagnosed and Treatable Cases in France (2019-2032)
  • Figure 9: Treatment-Resistant Depression (TRD) Epidemiology in Italy (2019-2032)
  • Figure 10: Treatment-Resistant Depression (TRD) Diagnosed and Treatable Cases in Italy (2019-2032)
  • Figure 11: Treatment-Resistant Depression (TRD) Epidemiology in Spain (2019-2032)
  • Figure 12: Treatment-Resistant Depression (TRD) Diagnosed and Treatable Cases in Spain (2019-2032)
  • Figure 13: Treatment-Resistant Depression (TRD) Epidemiology in the UK (2019-2032)
  • Figure 14: Treatment-Resistant Depression (TRD) Diagnosed and Treatable Cases in the UK (2019-2032)
  • Figure 15: Treatment-Resistant Depression (TRD) Epidemiology in Japan (2019-2032)
  • Figure 16: Treatment-Resistant Depression (TRD) Diagnosed and Treatable Cases in Japan (2019-2032)
  • Figure 17: Drug Name, Clinical Trials by Recruitment status
  • Figure 18: Drug Name, Clinical Trials by Zone
  • Figure 19: Total Seven Major Market Size in USD, Million (2019-2032)
  • Figure 20: Region-wise Market Size in USD, Million (2019-2032)
  • Figure 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)
  • Figure 22: United States Market Size in USD, Million (2019-2032)
  • Figure 23: United States Market Size by Therapy in USD, Million (2019-2032)
  • Figure 24: Germany Market Size in USD, Million (2019-2032)
  • Figure 25: Germany Market Size by Therapy in USD, Million (2019-2032)
  • Figure 26: France Market Size in USD, Million (2019-2032)
  • Figure 27: France Market Size by Therapy in USD, Million (2019-2032)
  • Figure 28: Italy Market Size in USD, Million (2019-2032)
  • Figure 29: Italy Market Size by Therapy in USD, Million (2019-2032)
  • Figure 30: Spain Market Size in USD, Million (2019-2032)
  • Figure 31: Spain Market Size by Therapy in USD, Million (2019-2032)
  • Figure 32: United Kingdom Market Size in USD, Million (2019-2032)
  • Figure 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)
  • Figure 34: Japan Market Size in USD, Million (2019-2032)
  • Figure 35: Japan Market Size by Therapy in USD, Million (2019-2032)

The list of figures is not exhaustive; the final content may vary